2200 PENNSYLVANIA AVE NW, WASHINGTON, DC
Reports First Quarter 2026 Financial Results
Annual Report to Security Holders
Appoints Dr. Charles Duncan to its Board of Directors
Executive Departure - Timothy Williams Resigns as SVP, General Counsel
FDA Approves Vanda's BYSANTI for Bipolar I and Schizophrenia
Changes in Board, Management or Compensation
Financial Results, Press Release
Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder
Q1
FY 2024
Q3
Q2
FY 2023
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Amended Registration of Securities
Registration of Securities
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload
Confidential Treatment Order